S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Critical asset just had biggest fall on record (Ad)
NASDAQ:ZVRA

Zevra Therapeutics (ZVRA) Stock Price, News & Analysis

$7.08
+0.34 (+5.04%)
(As of 03/1/2024 ET)
Today's Range
$6.71
$7.10
50-Day Range
$4.95
$7.08
52-Week Range
$3.89
$7.28
Volume
182,306 shs
Average Volume
238,179 shs
Market Capitalization
$256.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Zevra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
154.2% Upside
$18.00 Price Target
Short Interest
Bearish
5.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Zevra Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.15) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.27 out of 5 stars

Medical Sector

786th out of 950 stocks

Pharmaceutical Preparations Industry

354th out of 431 stocks


ZVRA stock logo

About Zevra Therapeutics Stock (NASDAQ:ZVRA)

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

ZVRA Stock Price History

ZVRA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Zevra Therapeutics Inc ZVRA
Zevra Therapeutics Resubmits Arimoclomol NDA To FDA
Zevra Therapeutics: Q3 Earnings Snapshot
Zevra Therapeutics appoints Neil McFarlane as its CEO
Zevra Therapeutics Names Neil McFarlane President, CEO
See More Headlines
Receive ZVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/02/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZVRA
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$25.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+154.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-41,540,000.00
Net Margins
-241.00%
Pretax Margin
-241.21%

Debt

Sales & Book Value

Annual Sales
$10.46 million
Book Value
$2.49 per share

Miscellaneous

Free Float
35,820,000
Market Cap
$256.44 million
Optionable
Optionable
Beta
1.82
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. R. LaDuane Clifton CPA (Age 52)
    CFO, Secretary, Treasurer & Director
    Comp: $563.22k
  • Mr. Neil F. McFarlane (Age 51)
    President, CEO & Director
  • Ms. Christal M. M. Mickle M.A. (Age 45)
    Co-Founder & Chief Development Officer
  • Dr. Sven Guenther Ph.D. (Age 52)
    Chief Scientific Officer
    Comp: $497.26k
  • Ms. Nichol L. Ochsner
    Vice President of Investor Relations & Corporate Communications
  • Dr. Christopher M. Lauderback Ph.D. (Age 49)
    Senior Vice President of Manufacturing
  • Dr. Rene A. Braeckman Ph.D.
    Senior Vice President of Clinical Development
  • Mr. Joshua M. Schafer M.B.A. (Age 52)
    Chief Commercial Officer, Executive VP of Business Development & Director
  • Dr. Daniel Gallo Ph.D.
    Senior Vice President of Medical Affairs & Advocacy
  • Dr. Adrian Quartel FFPM (Age 56)
    M.D., Chief Medical Officer














ZVRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Zevra Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZVRA shares.
View ZVRA analyst ratings
or view top-rated stocks.

What is Zevra Therapeutics' stock price target for 2024?

5 equities research analysts have issued 12 month price objectives for Zevra Therapeutics' shares. Their ZVRA share price targets range from $12.00 to $25.00. On average, they expect the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 154.2% from the stock's current price.
View analysts price targets for ZVRA
or view top-rated stocks among Wall Street analysts.

How have ZVRA shares performed in 2024?

Zevra Therapeutics' stock was trading at $6.55 at the beginning of the year. Since then, ZVRA stock has increased by 8.1% and is now trading at $7.08.
View the best growth stocks for 2024 here
.

When is Zevra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our ZVRA earnings forecast
.

What ETF holds Zevra Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 3,689 shares of ZVRA stock, representing 0.39% of its portfolio.

Who are Zevra Therapeutics' major shareholders?

Zevra Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (6.77%), Vanguard Group Inc. (4.54%), Janney Montgomery Scott LLC (1.89%), Northern Trust Corp (0.83%), Armistice Capital LLC (0.74%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Corey Michael Watton, John B Bode, Joshua Schafer, Matthew R Plooster, R Laduane Clifton, Richard W Pascoe, Tamara A Seymour and Timothy J Sangiovanni.
View institutional ownership trends
.

How do I buy shares of Zevra Therapeutics?

Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZVRA) was last updated on 3/2/2024 by MarketBeat.com Staff